` AMRN (Amarin Corporation PLC) vs S&P 500 Comparison - Alpha Spread

AMRN
vs
S&P 500

Over the past 12 months, AMRN has underperformed S&P 500, delivering a return of -3% compared to the S&P 500's 9% growth.

Stocks Performance
AMRN vs S&P 500

Loading
AMRN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
AMRN vs S&P 500

Performance Gap Between AMRN and GSPC
HIDDEN
Show

Performance By Year
AMRN vs S&P 500

Loading
AMRN
S&P 500
Add Stock

Competitors Performance
Amarin Corporation PLC vs Peers

S&P 500
AMRN
ABBV
AMGN
GILD
VRTX
Add Stock

Amarin Corporation PLC
Glance View

Market Cap
276.2m USD
Industry
Biotechnology

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

AMRN Intrinsic Value
HIDDEN
Show
Back to Top